Publications by authors named "Steven Blotner"

Claim this Profile
R
Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections.
Veeral S Sheth, Nancy M Holekamp, Arshad M Khanani, Aleksandra Rachitskaya, Steven Blotner

Ophthalmol Retina· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab.
Robert B Bhisitkul, Peter A Campochiaro, Steven Blotner, Carlos Quezada-Ruiz, Mimi Liu

Br J Ophthalmol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy.
Yasir Jamal Sepah, Diana V Do, Marina Mesquida, Bann-Mo Day, Steven Blotner

Eye (Lond)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drusen Characteristics and Age-Related Macular Degeneration in Fellow Eyes.
Caroline R Baumal, Steven Blotner, Anne E Fung, Carlos Quezada Ruiz

Ophthalmol Retina· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
K Bailey Freund, Giovanni Staurenghi, Jesse J Jung, Sandrine A Zweifel, Mariano Cozzi, Steven Blotner

Graefes Arch Clin Exp Ophthalmol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis.
Veeral Sheth, Mitchell D'Rozario, Shamika Gune, Steven Blotner

BMJ Open Ophthalmol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Antoine Italiano, Wilson H Miller, Jean-Yves Blay, Jourik A Gietema, Yung-Jue Bang, Steven Blotner

Invest New Drugs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Karen Yee, Cristina Papayannidis, Norbert Vey, Michael J Dickinson, Kevin R Kelly, Steven Blotner

Leuk Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Geoffrey L Uy, Sarit Assouline, Anne-Marie Young, Steven Blotner, Brian Higgins

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Albiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, Steven Blotner, Anne-Marie Young

Invest New Drugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [C]-labeled idasanutlin and an intravenous tracer dose of [C]-labeled idasanutlin in a single cohort of patients with solid tumors.
Zsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, Steven Blotner, Faye Vazvaei

Cancer Chemother Pharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R McWilliams, Marwan Fakih, Steven Blotner

Lancet Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
John Nemunaitis, Annie Young, Samuel Ejadi, Wilson Miller, Lin-Chi Chen, Steven Blotner

Cancer Chemother Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Steven Blotner, Lin-Chi Chen, Cristiano Ferlini, Jianguo Zhi

Cancer Chemother Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Peter N Morcos, Elena Guerini, Neil Parrott, Georgina Dall, Steven Blotner

Clin Pharmacol Drug Dev· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Bernhard Reis, Lori Jukofsky, Gong Chen, Giovanni Martinelli, Hua Zhong, Steven Blotner

Haematologica· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Michael Andreeff, Kevin R Kelly, Karen Yee, Sarit Assouline, Roger Strair, Steven Blotner

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Micaela B Reddy, Yuan Chen, Joshua O Haznedar, Jennifer Fretland, Steven Blotner

Clin Pharmacokinet· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects.
Dennis J Ahnen, Roberto Guerciolini, Jonathan Hauptman, Steven Blotner, Cindy J Woods

Clin Gastroenterol Hepatol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
Mitchell L Shiffman, Moisés Diago, Albert Tran, Paul Pockros, Robert Reindollar, Steven Blotner

Clin Gastroenterol Hepatol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
Daniele Prati, Mitchell L Shiffman, Moisés Diago, Edward Gane, K Rajender Reddy, Steven Blotner

J Hepatol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis